S. Vermeire

发表

[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)].

S. Travis, M. Sans, J. Lindsay, 2015, Revista de gastroenterologia de Mexico.

Corrections

M. Ranst, J. Verbeeck, G. V. Assche, 1994, Nature Biotechnology.

Patients with large‐duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD

S. Vermeire, F. Nevens, J. Pelt, 2016, Alimentary pharmacology & therapeutics.

Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis : Definitions and diagnosis

S. Travis, R. Eliakim, J. Lindsay, 2012 .

Postinfectious irritable bowel syndrome: a genetic link identified?

P. Rutgeerts, G. Van Assche, S. Vermeire, 2010, Gastroenterology.

Dose de‐escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease – a nested case–control study

S. Vermeire, A. Gils, M. Ferrante, 2017, Alimentary pharmacology & therapeutics.

Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management

S. Vermeire, S. Travis, M. Sans, 2012 .

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease

J. Belaiche, P. Rutgeerts, S. Vermeire, 2004, Alimentary pharmacology & therapeutics.

Short‐ and medium‐term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres

C. Buskens, W. Bemelman, S. Vermeire, 2017, The British journal of surgery.

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

S. Ng, J. Satsangi, M. Silverberg, 2021, Gastroenterology.

The impact of major depressive disorder on the short‐ and long‐term outcome of Crohn's disease treatment with infliximab

P. Rutgeerts, S. Vermeire, K. Demyttenaere, 2005, Alimentary pharmacology & therapeutics.

Antibiotic prophylaxis in gastrointestinal endoscopy

P. Rutgeerts, G. Assche, S. Ishaq, 2010, Gut.

High-throughput method for comparative analysis of denaturing gradient gel electrophoresis profiles from human fecal samples reveals significant increases in two bifidobacterial species after inulin-type prebiotic intake.

P. Rutgeerts, V. De Preter, M. Joossens, 2011, FEMS microbiology ecology.

Review article: altering the natural history of Crohn's disease – evidence for and against current therapies

P. Rutgeerts, S. Vermeire, G. Van Assche, 2006, Alimentary pharmacology & therapeutics.

Postoperative Inflammatory Response in Crohn's Patients: A Comparative Study.

S. Vermeire, M. Ferrante, G. Van Assche, 2015, Journal of Crohn's & colitis.

Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management

S. Travis, M. Sans, J. Lindsay, 2012 .

The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases

M. Daly, J. Rioux, A. Goris, 2007, Genes and Immunity.

FISH analysis of Lactobacillus biofilms in the gastrointestinal tract of different hosts

S. Lebeer, J. Vanderleyden, I. Claes, 2011, Letters in applied microbiology.

Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease

M. Dubinsky, S. Vermeire, U. Mahadevan, 2017, Alimentary pharmacology & therapeutics.

Therapeutic innovations in inflammatory bowel diseases

S. Vermeire, K. Nys, W. Vanhove, 2016, Clinical pharmacology and therapeutics.

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease

S. Vermeire, W. Sandborn, B. Feagan, 2017, Alimentary pharmacology & therapeutics.

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

P. Rutgeerts, S. Vermeire, A. Gils, 2014, Alimentary pharmacology & therapeutics.

Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease

G. Assche, S. Vermeire, Filip J. Baert, 2012, Alimentary pharmacology & therapeutics.

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.

B F Warren, S. Schreiber, S. Vermeire, 2008, Journal of Crohn's & colitis.

Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

K. Van Steen, S. Vermeire, T. Van Stappen, 2018, Alimentary pharmacology & therapeutics.

Prognostic factors for long‐term infliximab treatment in Crohn's disease patients: a 20‐year single centre experience

I. Cleynen, G. Assche, T. Billiet, 2016, Alimentary pharmacology & therapeutics.

Tumour necrosis factor‐α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab

P. Rutgeerts, S. Vermeire, P. Rutgeerts, 2004, Alimentary pharmacology & therapeutics.

Short- and long-term outcomes following side-to-side strictureplasty and its modification over the ileocecal valve for extensive Crohn's ileitis.

S. Vermeire, M. Ferrante, A. Wolthuis, 2020, Journal of Crohn's & colitis.

Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn’s disease

P. Lemey, P. Rutgeerts, S. Vermeire, 2001, Genes and Immunity.

Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis

P. Rutgeerts, S. Vermeire, G. V. Assche, 2010, Clinical and experimental immunology.

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

P. Rutgeerts, S. Vermeire, A. Gils, 2013, The American Journal of Gastroenterology.

OP035 Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease.

S. Vermeire, W. Sandborn, W. Reinisch, 2017, Journal of Crohn's & colitis.

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

S. Vermeire, I. Lawrance, G. D'Haens, 2015, Alimentary pharmacology & therapeutics.

Current status of genetics research in inflammatory bowel disease

P. Rutgeerts, S. Vermeire, P. Rutgeerts, 2005, Genes and Immunity.

Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease

P. Rutgeerts, S. Vermeire, P. Rutgeerts, 2002, Genes and Immunity.